Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected. Revenues grew 23% to $1.26 billion, vs. $1.24 billion expected. Sales of SOLIRIS (eculizumab) came in at $990.5 million, up 12% year-over-year. Raised FY19 revenue guidance to $4.86 – $4.89 billion vs. prior guidance of $4.75 – […]
“Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected. Revenues grew 23% to $1.26 billion, vs. $1.24 billion expected. Sales of SOLIRIS (eculizumab) came in at $990.5 million, up 12% year-over-year. Raised FY19 revenue guidance to $4.86 – $4.89 billion vs. prior guidance of $4.75 – […]
· October 23, 2019
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected.
Revenues grew 23% to $1.26 billion, vs. $1.24 billion expected. Sales of SOLIRIS (eculizumab) came in at $990.5 million, up 12% year-over-year.
Raised FY19 revenue guidance to $4.86 – $4.89 billion vs. prior guidance of $4.75 – $4.8 billion billion.
Adjusted EPS guidance for FY19 raised to a new range of $10.25 – $10.40, vs. earlier guidance of $9.65 – $9.85.
ALXN shares rose 1.7% immediately following the announcement.
